Biotech stocks with the fastest revenue growth

Ranked

36

of 146 biotech stocks we cover

Median

+26.6%

Highest

+292.2%

AUTL

Range

−61.6% to +292.2%

#	Company	Revenue growth	Net margin	Price to sales	Market cap
1	AUTLAutolus Therapeutics	+292.2%	n/m	3.5×	$409.9M
2	IBRXImmunityBio	+192.9%	n/m	52.5×	$8.7B
3	INSMInsmed	+185.8%	−76.9%	17.9×	$20.4B
4	BEAMBeam Therapeutics	+158.9%	−54.7%	15.9×	$2.5B
5	KYMRKymera Therapeutics	+134.8%	n/m	87.7×	$9.2B
6	TARSTarsus Pharmaceuticals	+105.2%	−7.7%	4.9×	$3B
7	ALNYAlnylam Pharmaceuticals	+95.1%	16.8%	6.2×	$30B
8	FENCFennec Pharmaceuticals	+77.8%	−5.5%	6.0×	$353.5M
9	BCRXBiocryst Pharmaceuticals	+68.7%	−40.9%	2.1×	$2B
10	CHRSCoherus Oncology	+61.0%	n/m	3.1×	$156M
11	ADPTAdaptive Biotechnologies	+50.1%	−20.7%	13.2×	$4.1B
12	HALOHalozyme Therapeutics	+41.2%	24.9%	8.6×	$14.3B
13	IOVAIovance Biotherapeutics	+34.5%	−89.1%	19.6×	$6.4B
14	NBIXNeurocrine Biosciences	+34.4%	20.9%	4.3×	$14.5B
15	ONCBeOne Medicines	+34.3%	10.7%	7.0×	$42.9B
16	AGENAgenus	+30.5%	69.3%	2.1×	$285M
17	PLXProtalix BioTherapeutics	+30.1%	23.5%	2.5×	$205.5M
18	INCYIncyte	+26.9%	27.7%	4.0×	$23.5B
19	IVVDInvivyd	+26.3%	n/m	3.1×	$180.8M
20	VCELVericel	+23.0%	7.9%	7.1×	$2.2B
21	KRYSKrystal Biotech	+22.6%	54.8%	20.9×	$9.2B
22	IMCRImmunocore	+21.0%	−4.2%	3.7×	$1.6B
23	TWSTTwist Bioscience	+19.2%	−31.7%	20.3×	$8.8B
24	RGENRepligen	+16.5%	5.3%	12.7×	$10B
25	RGNXREGENXBIO	+12.0%	n/m	2.5×	$441M
26	VRTXVertex Pharmaceuticals	+10.2%	35.0%	10.6×	$132.8B
27	REGNRegeneron Pharmaceuticals	+9.3%	27.9%	5.3×	$82.9B
28	EXELExelixis	+9.2%	35.3%	6.6×	$16B
29	ADMAAdma Biologics	+8.0%	33.0%	4.7×	$2.4B
30	CSBRChampions Oncology	+6.7%	−1.8%	1.1×	$65.7M
31	UTHRUnited Therapeutics	+2.5%	41.6%	8.0×	$25.2B
32	TECHBIO-TECHNE	−0.4%	15.0%	9.4×	$11.4B
33	RXRXRecursion Pharmaceuticals	−15.1%	n/m	36.1×	$2B
34	MRNAModerna	−27.6%	n/m	35.9×	$79.9B
35	DNAGinkgo Bioworks	−46.8%	n/m	6.0×	$672.7M
36	NVAXNovavax	−61.6%	−59.9%	3.9×	$1.6B

Not ranked: 32 with not a meaningful number, 32 with under $50M of revenue, 16 with a quarter missing, 6 with growth from a base too small to compare. 24 companies whose data behind this number has a caveat are left out until it is checked.

A ranking of numbers, not a recommendation. A low multiple can be a bargain or a business in trouble: open the company to see which.